{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"11","value":"4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"}],"units":"Participants"}],"title":"Turnaround Time: Plasma Genotyping"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8","upperLimit":"38","value":"20"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"title":"Turnaround Time: Tumor Genotyping"}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"}],"units":"Participants"}],"description":"The turnaround time from study registration to treatment initiation was recorded for the plasma genotyping strategy versus standard tumor genotyping. For rapid plasma genotyping, turnaround time is the time between ordering plasma genotyping and obtaining results; this time period was compared to the turnaround time of obtaining the tumor genotyping results.","dispersionType":"Full Range","groups":[{"description":"Participants who enrolled to the study and had plasma genotyping","id":"OG000","title":"Participants With Plasma Genotyping"}],"paramType":"MEDIAN","populationDescription":"A total of 42 participants had plasma genotyping results available (1 of the 43 enrolled participants did not have plasma genotyping).","reportingStatus":"POSTED","timeFrame":"Maximum 38 days","title":"Turnaround Time","type":"SECONDARY","unitOfMeasure":"days"}